Jason Chin
Founder
Constructive Bio
Constructive.Bio utilizes a dual-technology platform that combines de novo genome synthesis and engineered translation to create programmable biomolecules with high fidelity. This approach addresses the limitations of traditional biomanufacturing by enabling the production of customized bioproducts, including phage-resistant strains and next-generation therapeutics.
- Biotechnology
Updated 23 months ago
Funding
Raised to date
$73.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Traditional biomanufacturing processes face limitations in producing customized bioproducts and ensuring resilience against phage infections and horizontal gene transfer. Existing methods struggle to create programmable biomolecules with high fidelity and specificity, hindering advancements in therapeutics and industrial applications.
Solution
Constructive.Bio offers a dual-technology platform combining de novo genome synthesis and engineered translation to create programmable biomolecules. Their patented Syn61 strain expands the genetic code, enabling the production of customized biopolymers with unparalleled fidelity. This approach allows for the creation of phage-resistant strains and next-generation therapeutics. By hijacking the protein translation machinery of cells, Constructive.Bio produces sequence-defined biopolymers at scale, unlocking new dimensions in therapeutics, chemicals, and biomaterials. The platform's ability to produce strains resistant to phage infections and horizontal gene transfer ensures reliable, large-scale biomanufacturing.
Target Audience
The primary target audience includes companies in the therapeutics and industrial biomanufacturing sectors seeking to create customized bioproducts and enhance the resilience of their bioprocesses.
Features
- Patented Syn61 strain for expanding the genetic code
- De novo genome synthesis for creating customized biopolymers
- Engineered translation for producing sequence-defined biomolecules at scale
- Programmable biomolecules crafted with non-canonical building blocks
- Production of phage-resistant strains
- Technology applicable to therapeutics, chemicals, and biomaterials
- Built-in firewalls against phage attack and horizontal gene transfer